Novartis Cholesterol Drug Trial Fails, Triggering Sell-Off in Biopharma Sector

The news indicates that Novartis's cholesterol drug trial has failed, leading to a wave of selling in the biopharma sector. This negative development could put additional pressure on the stock. Technical indicators are also in oversold territory (RSI 10.3), and the price is well below both the 20-day and 50-day moving averages, pointing to a strong downtrend. In the short term, selling pressure is likely to persist, though some bargain buying may occur due to oversold conditions. Nevertheless, the primary trend is considered downward.

The news indicates that the failure of Novartis's cholesterol drug trial could create a wave of selling in the biopharma sector. PFE shares have already declined by 1.68% in the last 24 hours, with the RSI at 33.9, approaching oversold territory. The MACD is below the signal line and negative, indicating weak short-term momentum. The price is trading below the SMA20 and SMA50, which paints a negative technical picture. However, the sector-wide selloff may not directly impact PFE, so I expect a move to the downside with moderate confidence.

The news points to a negative development that could create a wave of selling in the biopharma sector. MRK's RSI is at 36, indicating weakness, and the price is below both the SMA20 and SMA50, suggesting negative short-term momentum. The MACD is below the signal line and approaching negative territory, indicating that selling pressure may continue. The 0.8% decline in the last close, combined with the impact of the news, increases the likelihood of further pullback in the short term. However, the direct impact of the sector-wide selling wave on MRK may be limited, so I foresee a cautious negative direction rather than a strong downtrend expectation.

BMY stock is already in oversold territory (RSI 24.9) and has dropped 2.8% in the last 24 hours. The news points to a sell-off wave in the biopharma sector, which could negatively impact BMY as well. MACD is negative and below the signal line, indicating weak short-term momentum. The price is below SMA20 and SMA50, confirming a bearish technical outlook. However, since RSI is oversold, the pace of decline may be limited, so confidence is moderate.